No description available.

No description available.

No description available.

No description available.

L'objectif de cette thèse est d'étudier la sensibilité des lignes cellulaires du cancer du sein BTCL aux agents stabilisants des microtubules (taxanes et ixabépilone) afin de: 1 - identifier la pharmaco-génomique prédictif de la réponse (résistance / sensibilité) comme une signature moleculaire, et de valider cette signature sur d'autres études dont les données génomiques sont disponibles en ligne, donc mis l'expression des gènes prédictifs de GES pour Tax- sensibilité (333 gènes ) et Ixa-sensibilité (79 gènes) ont été définis, et les Taxanes prédicateurs GES a considérablement prédit Pac-sensibilité dans BTCL, et pathologiques réponse complète à base de Pac-chimiothérapie néoadjuvante chez les patients du cancer du sein. 2 - étudier le rôle des cellules souches du cancer (ALDH +) sur la réponse thérapeutique aux Taxanes et donc, Nous identifions quatre lignes BTCL qui présentent un enrichissement significative dans le pourcentage et le nombre absolu de ALDELFUOR cellules positives dans chacun de ces quatre BTCLs après 5 jours de traitement par le paclitaxel, en contraste avec les résultats précédents, nous avons constaté que dans ces autres 3 BTCLs le phénomène est inversé avec la diminution significative du pourcentage et le nombre absolu de cellules positives ALDELFUOR trouve dans chacun de ces trois BTCLs après 5 jours du traitement par le paclitaxel. Une signature moléculaire de SCC résistant / sensible de 243 pb avec 179 gènes dont 152 gènes sont régulés à la hausse et 27 gènes régulés à la baisse au CSC résistantes au paclitaxel, une sorte prédicteurs génomiques pour Tax - sensibilité au CSC résistantes au paclitaxel peut être dérivée à partir BTCL et peut être utile pour mieux comprendre les mécanismes de résistance aux taxanes et de l'implication de la CSC dans cette résistance, afin de mieux sélectionner des traitements cytotoxiques chez les patients du cancer du sein et l'identification des d'autres marqueurs potentiels de thérapies ciblées dans l'avenir. 3 - Nous avons testé l'impact de l'altération des paramètres génomiques et protéiques ou les mutations de certains gènes comme tau (MAPT), K-alpha tubuline (TUB A1B) tubuline alpha-6 (A1C TUB) tubuline beta 3 (TUBB3) et stathmine (STMN1), malheureusement nous n'avions jamais identifier une mutation pour être corrélée à la réponse des BTCL aux Taxanes. 4 - Nous essayons d'étudier au niveau de protéines par immunohistochimie sur le tissu de micro-array et cyto-micro-array pour certains paramètres qui ont été déjà prouvé (in vitro) pour être corrélée à la réponse aux Taxanes, (cette partie est en fait en cours). / The aim of this thesis is to study the sensitivity of breast cancer cell lines BTCL to microtubule-stabilizing agents (Taxanes and ixabepilone) in order to:1- identify pharmaco-genomic predictor of response (resistance /sensitivity) as a molecular signature, and to validate this signature on others studies of which the genomic data are available on line, so gene expression set GES predictors for Tax-sensitivity (333 genes) and Ixa-sensitivity (79 genes) were defined, and the Taxanes GES predictors has significantly predicted Pac-sensitivity in BTCL, and pathological complete response to Pac-based neo-adjuvant chemotherapy in BC patients.2- study the role of cancer stem cell (ALDH+) on the therapeutic response to Taxanes and their we identify 4 BTCLs which present a significant enrichment in the percentage and the absolute numbers of ALDELFUOR-positive cells found in each of these 4 BTCLs after 5 days of treatment by Paclitaxel , In contrast to the previous results we found that in others 3 BTCLs these phenomenon is inversed with the significant decrease of the percentage, and the absolute numbers of ALDELFUOR-positive cells found in each of these 3 BTCLs after 5 days of treatment by Paclitaxel.A molecular signature of CSC resistant /sensitive of 243 pb with 179 genes of which 152 genes are up- regulated and 27 genes down-regulated in CSC resistant to Paclitaxel, so a genomic predictors for Tax-sensitivity in CSC resistant to Paclitaxel can be derived from BTCL and may be helpful for better understanding the mechanisms of resistance to Taxanes and the implication of CSC in this resistance in order to better select of cytotoxic treatment in breast cancer patients and identification of others potential markers for targeted therapies in the future .3- we tested the impact of the alteration of genomic and proteic parameters or the mutations of some genes like tau (MAPT),Tubulin K- ALPHA (TUB A1B) Tubulin alpha-6 (TUB A1C) Tubulin beta 3 (TUBB3) and Stathmin (STMN1), unfortunately we did'nt identify a mutations to be correlated to BTCL response to Taxanes .4- we try to study at the level of proteins by immunohistochemistry on the tissue micro- array and cyto-micro-array for some parameters which have been already proved (in vitro) to be correlated with response to Taxanes , ( this part is actually ongoing).

La survenue d’un cancer du sein découvert durant la grossesse est un événement dramatique compliquant entre 1/3000 et 1/10000 grossesses, ce qui en fait le cancer le plus fréquemment rencontré chez la femme enceinte. Sur le plan thérapeutique, certaines molécules anticancéreuses peuvent être utilisées, notamment les taxanes (paclitaxel et docétaxel). Si les études cliniques rétrospectives isolées semblent plutôt rassurantes, les données concernant leur passage transplacentaire sont encore fragmentaires. Quant à leurs effets sur le placenta humain et plus particulièrement sur la fonction de transport placentaire, ils sont pour l’heure inconnus. Nos objectifs étaient de 1) dresser une cartographie de l’expression génique physiologique des différents transporteurs placentaires de médicaments en utilisant un modèle de culture primaire trophoblastique, 2) d’apprécier le passage transplacentaire comparatif des taxanes et leur accumulation placentaire en utilisant le modèle du cotylédon perfusé, 3) d’étudier plus particulièrement les effets du paclitaxel sur le placenta humain et notamment sur l’expression des transporteurs de médicaments, en utilisant en plus des modèles mentionnés, les cotylédons de patientes ayant été traitées par paclitaxel durant leur grossesse. Nos études ont tout d’abord permis de dresser une cartographie originale de l’expression physiologique de plus de 80 transporteurs placentaires de médicaments, et ce comparativement entre le début et la fin de la gestation. De plus, nos expériences ont montré que le passage transplacentaire des taxanes était faible et comparable entre les deux molécules, et que celles-ci semblaient s’accumuler dans les cotylédons placentaires. Enfin, nous avons pu mettre en évidence un effet significatif du paclitaxel sur le placenta humain, notamment sur la modulation de certains transporteurs de médicaments. / The occurrence of breast cancer during pregnancy is a dramatic event reaching roughly 1/3000 to 1/10000 pregnancies, this type of cancer being the most frequent in pregnant women. Regarding therapeutic options, some anticancer agents may be used, especially taxanes (paclitaxel and docetaxel). If most of retrospective data appear to be reassuring, little is known regarding their transplacental transfer. Moreover, to our knowledge, potential effects of taxanes on human placenta, especially on placental transport function are unknown. Our aims were to 1) provide a transcriptional expression cartography of various placental drug transporters throughout pregnancy, using primary trophoblast culture model, 2) assess the comparative transplacental transfer of taxanes and their accumulation in cotyledons, using the perfused placental model, 3) assess potential effects of paclitaxel on human placenta, especially on drug transporter expression, not only using above-described models, but also cotyledons from pregnant-cancer patients treated with paclitaxel during pregnancy. Here, we finally provided an original transcriptional cartography of various drugs transporters in human normal placenta all along pregnancy. Moreover, we found a low and comparable transplacental transfer of paclitaxel and docetaxel that led to a moderate accumulation in cotyledons. Finally, we evidenced a significant effect of paclitaxel on human placenta, especially by modulating drug transporter expression.

Ovarian carcinoma is a serious illness with the highest mortality rate among all female cancers. No suitable methods for early diagnosis, precise determination of prognosis or prediction of therapy efficacy are currently available, which leads to diagnosis in advanced stages of disease and therapy efficacy limitation. Consequently, the development of chemoresistance to conventional drugs and frequent relapse of the disease pose a fundamental complication too. The main goal of the current study was identification of new putative prognostic and therapeutic biomarkers, whose introduction into clinical practice could help to improve the dismal outcome of ovarian carcinoma patients. The present master thesis provides results of expression analysis of genes whose products take part in the transport, metabolism and mechanism of action of platinum based drugs and taxanes, and also the regulation of cell cycle and signaling. Transcript levels of these genes have been assessed in series of tumor and control ovarian tissue samples and the difference between both tissue types was evaluated. Gene expression level in tumors was then compared with patient's clinical data and candidate genes, ABCA2 and PRC1, were selected from the obtained results for more detailed analysis. The protein level of candidate genes...

No description available.

Taxol (generic name paclitaxel), a plant‐derived antineoplastic agent, was originally isolated from the bark of the Pacific yew, Taxus brevifolia. Obtaining taxol from this source requires destruction of trees. It has been used alone or in combination with other chemotherapeutic agents for the treatment of breast, ovarian as well as many other types of cancer, including non‐small cell lung carcinoma, prostate, head and neck cancer, and lymphoma, as well as AIDSrelated Kaposi’s sarcoma. The mode of action of taxol against a number of human cancer cells is by preventing the depolymerization of tubulin during cell division. This molecule increases microtubule stability in the cell and induces apoptosis. From yew trees, the yield of taxol is usually between 0.004 to 0.1% of the dry weight. The commercial isolation of 1 Kg of taxol requires about 6 to 7 tons of T. brevifolia bark obtained from 2000‐3000 well‐grown trees. The limited supply of the drug has prompted efforts to find alternative sources of taxol. Alternative methods for taxol production, such as chemical synthesis, tissue and cell cultures of the Taxus species are expensive and give low yields. A fermentation process involving any microorganism would be the most desirable means to lower the cost and increase availability. The first report on the isolation of taxol‐producing fungi from Taxus brevifolia appeared in 1993 (Stierle, et al., 1993). Several taxol‐producing fungi have been identified since, such as Taxomyces andreanae, Taxodium disticum, Tubercularia sp., Pestalotiopsis microspora, Alternaria sp., Fusarium maire and Periconia sp (Li, et al., 1996, Strobel, et al., 1996a, Strobel, et al., 1996b, Li, et al., 1998b, Ji, et al., 2006, Xu, et al., 2006). This thesis investigates the isolation of an endophytic fungus, isolated from the stem cuttings of Taxus celebica, which produces taxol and related taxanes. We observed morphological and cultural characteristics and analyzed the sequences of rDNA ITS from the strain. The isolated fungus grew on potato carrot agar (PCA) medium at 25 °C and the colonies were white to off‐white, floccose, with irregular margins. The reverse side of the culture was cream in color. The morphology was examined microscopically following staining with cotton blue in lactophenol. Cultures produced macroconidia on slender, 85 μm long phialides. The macroconidia were 25‐40 X 3.75 μm. Cultures also produced round or oval microconidia. Analysis of the ITS and D1/D2 26S rDNA sequence revealed 99 % identity with Fusarium solani voucher NJM 0271. Based on its morphological, cultural characteristics and 26S rDNA sequence, the fungus was identified as F. solani. This fungus is different from the previously reported endophytic taxol‐producing species of Fusarium. Taxol and baccatin III, produced by this fungus, were identified by chromatographic and spectroscopic comparison with standard compounds. The amount of taxol produced by F. solani in potato dextrose liquid medium is low (1.6 μg l‐1) (Chakravarthi, et al., 2008). We further investigated different growth media and various factors of cultivation to select the medium and conditions that maximize production of taxol and other taxanes by this fungus. F. solani was grown in five well‐defined culture media under stationary and shake conditions separately for various time intervals and the amounts of taxol, baccatin III and other taxanes produced were estimated by competitive immunoassay. The modified flask basal medium (MFBM) was shown to yield the highest production of taxol (128 μg l‐1) which is 80 times more than when grown in potato dextrose liquid medium, baccatin III (136 μg l‐1) and total taxanes (350 μg l‐1) under shake conditions. From our results the highest taxol production of F. solani was achieved when cultured in MFBM. The production in MFBM was 80 times higher than that cultured in the potato dextrose liquid medium. In conclusion, it was shown that the culture medium plays a major role in taxol and other taxanes production and fungal growth. MFBM is the best medium, among the media studied, to produce taxol and other taxanes. The higher concentrations of NH4NO3, MgSO4, KH2PO4 and FeCl3 in the FBM medium seem important for production of taxol and other taxanes. These results can be considered as starting‐point for the research directed to improve taxol and baccatin III production by F. solani via different approaches including fermentations, strain improvement and genetic engineering techniques. Finally, in order to get more insights into the mode of action of this fungal taxol and baccatin III (for the first time), their apoptotic activity on different cancer cell lines was determined. We elucidated the biochemical pathways leading to apoptotic cell death after fungal taxol‐ and baccatin III‐ treatment in different cancer cell lines. Experiments are done on various cancer cell lines namely JR4 Jurkat (T‐cell leukemia), J16 Bcl‐2 Jurkat T cells, HepG2 (hepatoma), caspase‐8‐deficient Jurkat T cells, HeLa (human cervical carcinoma), Ovcar3 (human ovarian carcinoma) and T47D (human breast carcinoma) cells. We were able to demonstrate that both fungal taxol and baccatin III can induce apoptosis in all the cell lines tested, by flow cytometric analysis. Hallmarks of apoptosis following the signaling pathway to far more upstream‐located events were investigated using biochemical and cell biological methods. It has shown that during fungal taxol‐ and baccatin III‐induced apoptosis, DNA is degraded resulting in a increased number of hypodiploid cells reaching up to 65‐70% after 48 h. Disruption of mitochondrial membrane potential was examined by flow cytometric analysis using mitochondrial membrane potential sensitive dye JC‐1 and JR4‐Jurkat cells were shown to undergo significant loss of mitochondrial membrane potential loss of mitochondrial membrane potential reaching up to 70% in 6 nM fungal taxol and 65 % in 3.5 μM baccatin III after 36 h. These results were similar to those observed with standard taxol and baccatin III. We further investigated the role of caspases in fungal taxol‐ and baccatin III‐induced apoptosis, caspase‐8‐deficient Jurkat cells, Bcl‐2‐over‐expressed J16‐Jurkat cells and caspase inhibitors were used. Results derived from caspase‐8‐deficient Jurkat cells show that caspase‐8 is not involved in fungal taxol‐ and baccatin IIIinduced apoptosis of Jurkat cells. Using the pan‐caspase inhibitor (Z‐VAD‐FMK), caspase‐9 inhibitor (Z‐LEHD‐FMK), caspase‐3‐inhibitor (Z‐DEVD‐FMK), caspase‐2‐ inhibitor (Z‐VDVAD‐FMK) and caspase 10‐inhibitor (Z‐AEVD‐FMK), it was shown that caspase‐10 is involved in fungal taxol‐ and baccatin III‐ induced apoptosis in JR4‐Jurkat cells. It was also shown that inhibitors of caspases‐9, ‐2 or ‐3 partially inhibited fungal taxol‐ and baccatin III‐ induced apoptosis, whereas the caspase‐ 10 inhibitor totally abrogated this process. With the use of a fluorescence microscope, several morphological features characteristic of apoptosis such as condensed chromatin and apoptotic bodies were identified in fungal taxol‐ and baccatin III‐treated JR4‐Jurkat and HeLa cells. DNA fragmentations were shown by agarose gel electrophoresis method. Our work showed that treatment of JR4‐ Jurkat and HepG2 cells with fungal taxol and baccatin III induces apoptosis as shown by DNA ladder formation. Herein it was demonstrated that fungal taxol and baccatin III have a similar mechanism of action, but the efficacy of fungal taxol to induce apoptosis is higher. In summary, fungal baccatin III is found to be effective in inducing apoptosis similar to taxol but at higher concentration and both fungal taxol and baccatin III induce apoptosis via caspase‐10 and mitochondrial pathway in Jurkat cells. In conclusion, the present study describes isolation of a taxol‐producing endophyte F. solani IISc.CJB‐1. The growth requirements of this fungus for production of taxol, baccatin III and other taxanes were studied. The apoptotic activity of taxol and baccatin III (for the first time) was observed. In addition, our results show that the culture medium plays a major role in taxol and other taxanes production and fungal growth. Among the media studied, modified flask basal medium (MFBM) is the best to produce taxol and other taxanes. It is evident from this data that this fungal strain can be promising candidate for large‐scale production of taxol and related taxanes.

Ovarian cancer is the most common cause of death from gynecological malignancy. Taxanes and platinum derivatives are most used therapeutics for its treatment. Development of multi drug resistance to chemotherapy represents a serious complication of the treatment. Therefore, new chemotherapeutic and therapeutic targets are investigated, which could help to overcome tumor cell resistance. The main objectives of the thesis were to study: i) the efficiency of new derivatives of conventional taxanes in vitro with the aim to determine the potentially most effective taxane derivatives in resistant tumor ovarian cells and, ii) the gene expression profile of the Notch signaling pathway, as a possible therapeutic target for the treatment of ovarian cancer. Specifically, the thesis focused on the relationship between levels of Notch signaling gene expression in patients with ovarian carcinoma and their prognosis, progression and survival. This thesis revealed that Stony Brook Taxanes - "SB-T"; SB-T-121402, SB-T-121605, and SB-T-121606 derivatives are very effective in NCI/ADR-RES tumor carcinoma cells resistant to conventional taxane - paclitaxel, and should be further studied in more advanced models, e.g. in vivo patient derived xenografts. In a study of the importance of the Notch signaling pathway in...